Cargando…

Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis

BACKGROUND: Quantifying the benefits and harms of breast cancer screening accurately is important for planning and evaluating screening programs and for enabling women to make informed decisions about participation. However, few cohort studies have attempted to estimate benefit and harm simultaneous...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sabrina, Sultana, Farhana, Kavanagh, Anne, Nickson, Carolyn, Karahalios, Amalia, Gurrin, Lyle C., English, Dallas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524083/
https://www.ncbi.nlm.nih.gov/pubmed/37548277
http://dx.doi.org/10.1002/cam4.6373
_version_ 1785110674991480832
author Wang, Sabrina
Sultana, Farhana
Kavanagh, Anne
Nickson, Carolyn
Karahalios, Amalia
Gurrin, Lyle C.
English, Dallas R.
author_facet Wang, Sabrina
Sultana, Farhana
Kavanagh, Anne
Nickson, Carolyn
Karahalios, Amalia
Gurrin, Lyle C.
English, Dallas R.
author_sort Wang, Sabrina
collection PubMed
description BACKGROUND: Quantifying the benefits and harms of breast cancer screening accurately is important for planning and evaluating screening programs and for enabling women to make informed decisions about participation. However, few cohort studies have attempted to estimate benefit and harm simultaneously. AIMS: We aimed to quantify the impact of mammographic screening on breast cancer mortality and overdiagnosis using a cohort of women invited to attend Australia's national screening program, BreastScreen. METHODS: In a cohort of 41,330 women without prior breast cancer diagnosis, screening, or diagnostic procedures invited to attend BreastScreen Western Australia in 1994‐1995, we estimated the cumulative risk of breast cancer mortality and breast cancer incidence (invasive and ductal carcinoma in situ) from age 50 to 85 years for attenders and non‐attenders. Data were obtained by linking population‐based state and national health registries. Breast cancer mortality risks were estimated from a survival analysis that accounted for competing risk of death from other causes. Breast cancer risk for unscreened women was estimated by survival analysis, while accounting for competing causes of death. For screened women, breast cancer risk was the sum of risk of being diagnosed at first screen, estimated using logistic regression, and risk of diagnosis following a negative first screen estimated from a survival analysis. RESULTS: For every 1,000 women 50 years old at first invitation to attend BreastScreen, there were 20 (95% CI 12‐30) fewer breast cancer deaths and 25 (95% CI 15‐35) more breast cancers diagnosed for women who attended than for non‐attendees by age 85. Of the breast cancers diagnosed in screened women, 21% (95% CI 13%‐27%) could be attributed to screening. DISCUSSION: The estimated ratio of benefit to harm was consistent with, but slightly less favourable to screening than most other estimates from cohort studies. CONCLUSION: Women who participate in organised screening for breast cancer in Australia have substantially lower breast cancer mortality, while some screen‐detected cancers may be overdiagnosed.
format Online
Article
Text
id pubmed-10524083
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105240832023-09-28 Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis Wang, Sabrina Sultana, Farhana Kavanagh, Anne Nickson, Carolyn Karahalios, Amalia Gurrin, Lyle C. English, Dallas R. Cancer Med RESEARCH ARTICLES BACKGROUND: Quantifying the benefits and harms of breast cancer screening accurately is important for planning and evaluating screening programs and for enabling women to make informed decisions about participation. However, few cohort studies have attempted to estimate benefit and harm simultaneously. AIMS: We aimed to quantify the impact of mammographic screening on breast cancer mortality and overdiagnosis using a cohort of women invited to attend Australia's national screening program, BreastScreen. METHODS: In a cohort of 41,330 women without prior breast cancer diagnosis, screening, or diagnostic procedures invited to attend BreastScreen Western Australia in 1994‐1995, we estimated the cumulative risk of breast cancer mortality and breast cancer incidence (invasive and ductal carcinoma in situ) from age 50 to 85 years for attenders and non‐attenders. Data were obtained by linking population‐based state and national health registries. Breast cancer mortality risks were estimated from a survival analysis that accounted for competing risk of death from other causes. Breast cancer risk for unscreened women was estimated by survival analysis, while accounting for competing causes of death. For screened women, breast cancer risk was the sum of risk of being diagnosed at first screen, estimated using logistic regression, and risk of diagnosis following a negative first screen estimated from a survival analysis. RESULTS: For every 1,000 women 50 years old at first invitation to attend BreastScreen, there were 20 (95% CI 12‐30) fewer breast cancer deaths and 25 (95% CI 15‐35) more breast cancers diagnosed for women who attended than for non‐attendees by age 85. Of the breast cancers diagnosed in screened women, 21% (95% CI 13%‐27%) could be attributed to screening. DISCUSSION: The estimated ratio of benefit to harm was consistent with, but slightly less favourable to screening than most other estimates from cohort studies. CONCLUSION: Women who participate in organised screening for breast cancer in Australia have substantially lower breast cancer mortality, while some screen‐detected cancers may be overdiagnosed. John Wiley and Sons Inc. 2023-08-07 /pmc/articles/PMC10524083/ /pubmed/37548277 http://dx.doi.org/10.1002/cam4.6373 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Wang, Sabrina
Sultana, Farhana
Kavanagh, Anne
Nickson, Carolyn
Karahalios, Amalia
Gurrin, Lyle C.
English, Dallas R.
Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
title Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
title_full Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
title_fullStr Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
title_full_unstemmed Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
title_short Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis
title_sort benefits and harms of breast cancer screening: cohort study of breast cancer mortality and overdiagnosis
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524083/
https://www.ncbi.nlm.nih.gov/pubmed/37548277
http://dx.doi.org/10.1002/cam4.6373
work_keys_str_mv AT wangsabrina benefitsandharmsofbreastcancerscreeningcohortstudyofbreastcancermortalityandoverdiagnosis
AT sultanafarhana benefitsandharmsofbreastcancerscreeningcohortstudyofbreastcancermortalityandoverdiagnosis
AT kavanaghanne benefitsandharmsofbreastcancerscreeningcohortstudyofbreastcancermortalityandoverdiagnosis
AT nicksoncarolyn benefitsandharmsofbreastcancerscreeningcohortstudyofbreastcancermortalityandoverdiagnosis
AT karahaliosamalia benefitsandharmsofbreastcancerscreeningcohortstudyofbreastcancermortalityandoverdiagnosis
AT gurrinlylec benefitsandharmsofbreastcancerscreeningcohortstudyofbreastcancermortalityandoverdiagnosis
AT englishdallasr benefitsandharmsofbreastcancerscreeningcohortstudyofbreastcancermortalityandoverdiagnosis